Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Tournier, Benjamin ^a,b   Chapusot, Caroline ^a,b   Courcet, Emilie ^a,b   Martin, Laurent ^b,c   Lepage, Côme ^a,b   Faivre, Jean ^a,b   Piard, Françoise ^a,b,c  

^a Chu   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c Centre de ressources biologiques Ferdinand Cabanne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; DNA; DNA METHYLTRANSFERASE; HYDROGEN SULFITE; MGMT PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PARAFFIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SULFITE; TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; CRYOPRESERVATION; DNA EXTRACTION; DNA METHYLATION; EPIGENETICS; HUMAN; HUMAN TISSUE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PYROSEQUENCING; QUALITATIVE ANALYSIS; REPRODUCIBILITY; TISSUE SECTION; ADENOCARCINOMA; COLON TUMOR; COMPARATIVE STUDY; FEASIBILITY STUDY; GENETICS; LONG INTERSPERSED REPEAT; METABOLISM; PREDICTIVE VALUE; PROGNOSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; COLONIC NEOPLASMS; CPG ISLANDS; CRYOPRESERVATION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEASIBILITY STUDIES; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PARAFFIN EMBEDDING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SULFITES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84855753539     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-12     Document Type: Article

References (31)

1. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159. 10.1056/NEJMra072067, 18337604.
2. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004, 4:988-993. 10.1038/nrc1507, 15573120.
3. Wong JJ, Hawkins NJ, Ward RL. Colorectal cancer: a model for epigenetic tumorigenesis. Gut 2007, 56:140-148. 10.1136/gut.2005.088799, 1856668, 16840508.
4. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999, 96:8681-8686. 10.1073/pnas.96.15.8681, 17576, 10411935.
5. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008, 68:8541-8546. 10.1158/0008-5472.CAN-08-1171, 18922929.
6. Ferracin M, Gafa R, Miotto E, Veronese A, Pultrone C, Sabbioni S, Lanza G, Negrini M. The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. J Pathol 2008, 214:594-602. 10.1002/path.2318, 18241079.
7. Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008, 58:104-113. 10.1111/j.1440-1827.2007.02197.x, 18199160.
8. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 2007, 450:529-537. 10.1007/s00428-007-0398-3, 17372756.
9. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58:90-96. 10.1136/gut.2008.155473, 2679586, 18832519.
10. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005, 65:6063-6069. 10.1158/0008-5472.CAN-05-0404, 16024606.
11. Shen L, Catalano PJ, Benson AB, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007, 13:6093-6098. 10.1158/1078-0432.CCR-07-1011, 17947473.
12. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003, 9:2898-2903.
13. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003, 21:3729-3736. 10.1200/JCO.2003.03.123, 14551292.
14. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992, 89:1827-1831. 10.1073/pnas.89.5.1827, 48546, 1542678.
15. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994, 22:2990-2997. 10.1093/nar/22.15.2990, 310266, 8065911.
16. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 11:191-203.
17. Uhlmann K, Brinckmann A, Toliat MR, Ritter H, Nurnberg P. Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis 2002, 23:4072-4079. 10.1002/elps.200290023, 12481262.
18. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004, 32:e38. 10.1093/nar/gnh032, 373427, 14973332.
19. Kristensen LS, Wojdacz TK, Thestrup BB, Wiuf C, Hager H, Hansen LL. Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM. BMC Cancer 2009, 9:453. 10.1186/1471-2407-9-453, 2804714, 20025721.
20. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997, 57:4749-4756.
21. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002, 123:1804-1811. 10.1053/gast.2002.37070, 12454837.
22. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 2006, 66:5495-5503. 10.1158/0008-5472.CAN-05-2385, 16707479.
23. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M, Laird PW. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005, 33:6823-6836. 10.1093/nar/gki987, 1301596, 16326863.
24. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D, Voravud N, Sriuranpong V, Mutirangura A. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 2004, 23:8841-8846. 10.1038/sj.onc.1208137, 15480421.
25. Phokaew C, Kowudtitham S, Subbalekha K, Shuangshoti S, Mutirangura A. LINE-1 methylation patterns of different loci in normal and cancerous cells. Nucleic Acids Res 2008, 36:5704-5712. 10.1093/nar/gkn571, 2553567, 18776216.
26. Toyota M, Suzuki H. Epigenetic drivers of genetic alterations. Adv Genet 70:309-323.
27. Mirchev MB, Kahl P, Friedrichs N, Kotzev IA, Buettner R. DNA methylation in patients with colorectal cancer--correlation with some clinical and morphological features and with local tumour invasion. Folia Med (Plovdiv) 52:22-30.
28. Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, Hayashi M, Giovannucci E, Fuchs CS, Ogino S. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control 22:301-309.
29. Kagan J, Srivastava S, Barker PE, Belinsky SA, Cairns P. Towards clinical application of methylated DNA sequences as cancer biomarkers: a joint NCI's EDRN and NIST workshop on standards, methods, assays, reagents and tools. Cancer Res 2007, 67:4545-4549. 10.1158/0008-5472.CAN-06-2888, 17510378.
30. Irahara N, Nosho K, Baba Y, Shima K, Lindeman NI, Hazra A, Schernhammer ES, Hunter DJ, Fuchs CS, Ogino S. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn 12:177-183.
31. Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006, 8:209-217. 10.2353/jmoldx.2006.050135, 1867588, 16645207.